MACK
Merrimack Pharmaceuticals, Inc.
MACK
MACK
Delisted
MACK was delisted on the 17th of May, 2024.
47 hedge funds and large institutions have $81.2M invested in Merrimack Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
15% more funds holding
Funds holding: 41 → 47 (+6)
Holders
47
Holding in Top 10
3
Calls
$6.49M
Puts
$3.63M
Top Buyers
| 1 | +$4.09M | |
| 2 | +$2.87M | |
| 3 | +$2.45M | |
| 4 |
O
OrbiMed
New York
|
+$843K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$736K |
Top Sellers
| 1 | -$4.13M | |
| 2 | -$2.52M | |
| 3 | -$2.47M | |
| 4 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$345K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$227K |